descriptionPublicationkeyboard_double_arrow_right Article 14 May 2018 English Publisher:CMA Impact Inc.Journal:Canadian Medical Association Journal, volume 190, pages E596-E596 (issn: 0820-3946, eissn: 1488-2329,

Authors: Taleen, Karnieg; Xiang, Wang;

doi: 10.1503/cmaj.171371

pmid: 29759967

pmc: PMC5953578

Cytisine for smoking cessation

- Summary
- Subjects
- Metrics

Abstract

Cytisine, primarily derived from the Cytisus laburnum plant (which inspired the development of varenicline), is a partial agonist of the α4β2 nicotinic acetylcholine receptor responsible for central effects of nicotine.[1][1] Oral cytisine reaches peak concentration two hours postdose[2][2] and is

Related Organizations

University of Toronto
Canada
Ottawa Hospital
Canada

Keywords

Nicotine, Alkaloids, Treatment Outcome, Meta-Analysis as Topic, Humans, Smoking Cessation, Nicotinic Agonists, Azocines, Quinolizines, Systematic Reviews as Topic

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	23
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average